LAVAL, QC, Dec. 9, 2016 /CNW Telbec/ - ProMetic Life Sciences
Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation") responded today to a false market data report
listing amongst others, Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic, as a
net seller of 8.85 million shares of ProMetic. This report is false and inaccurate. All insider activities, including those of Mr.
Laurin, have been properly disclosed and filed on SEDI. Furthermore, the Corporation is unaware of any corporate developments to
account for the recent decline in share price and trading activity.
While the Corporation does not generally comment publicly on market speculation or rumours, the Corporation believed it was
prudent to advise investors that the report is false and that the Corporation's CEO has not sold 8.85 million shares of the
Corporation. The Corporation does not anticipate issuing any further public statement regarding any rumours or speculation in the
marketplace unless required by applicable laws.
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (www.prometic.com) is a long
established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and
small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug
development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology
that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop
best-in-class therapeutics and orphan drugs. ProMetic is also active in developing its own novel small-molecule therapeutic
products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune diseases/inflammation
as well as certain nephropathies. Headquartered in Laval (Canada), ProMetic has R&D facilities
in the UK, the U.S. and Canada, manufacturing facilities in the UK and commercial activities in the U.S., Canada, Europe, Russia, Asia and Australia.
Forward Looking Statements
This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and
successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects,
the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in
the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will
find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current
expectations in ProMetic's Annual Information Form for the year ended December 31, 2015, under the
heading "Risk and Uncertainties related to ProMetic's business". As a result, we cannot guarantee that any forward-looking
statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes
available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All
amounts are in Canadian dollars unless indicated otherwise.
SOURCE ProMetic Life Sciences Inc.